Trial Profile

A Single-arm, Dose-escalating Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetic , and Efficacy of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MT 027 (Primary) ; MT 027 (Primary)
Indications Brain metastases; Breast cancer; CNS cancer; Colorectal cancer; Glioma; Lung cancer; Malignant melanoma; Meningeal carcinomatosis; Renal cell carcinoma; Solid tumours
Focus Adverse reactions
Sponsors Suzhou Maximum Bio-tech

21 Jul 2026 According to T-Maximum Pharmaceutical media release, abstract from the trial has been accepted by the conference in the brain-metastasis setting and will be formally disclosed this September.
25 Dec 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com